JP2016163571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016163571A5 JP2016163571A5 JP2016039171A JP2016039171A JP2016163571A5 JP 2016163571 A5 JP2016163571 A5 JP 2016163571A5 JP 2016039171 A JP2016039171 A JP 2016039171A JP 2016039171 A JP2016039171 A JP 2016039171A JP 2016163571 A5 JP2016163571 A5 JP 2016163571A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- galactosidase
- specific pharmacological
- pharmacological chaperone
- gala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2814108P | 2008-02-12 | 2008-02-12 | |
| US61/028,141 | 2008-02-12 | ||
| US3568408P | 2008-03-11 | 2008-03-11 | |
| US61/035,684 | 2008-03-11 | ||
| US9363108P | 2008-09-02 | 2008-09-02 | |
| US61/093,631 | 2008-09-02 | ||
| US11349608P | 2008-11-11 | 2008-11-11 | |
| US61/113,496 | 2008-11-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014244283A Division JP2015091239A (ja) | 2008-02-12 | 2014-12-02 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018245609A Division JP6837469B2 (ja) | 2008-02-12 | 2018-12-27 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016163571A JP2016163571A (ja) | 2016-09-08 |
| JP2016163571A5 true JP2016163571A5 (https=) | 2016-12-01 |
| JP6672013B2 JP6672013B2 (ja) | 2020-03-25 |
Family
ID=40957500
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010546901A Active JP5844045B2 (ja) | 2008-02-12 | 2009-02-12 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2014244283A Pending JP2015091239A (ja) | 2008-02-12 | 2014-12-02 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2016039171A Active JP6672013B2 (ja) | 2008-02-12 | 2016-03-01 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2018245609A Active JP6837469B2 (ja) | 2008-02-12 | 2018-12-27 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2021019383A Active JP7277493B2 (ja) | 2008-02-12 | 2021-02-09 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2023076515A Withdrawn JP2023109807A (ja) | 2008-02-12 | 2023-05-08 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2025097940A Pending JP2025148351A (ja) | 2008-02-12 | 2025-06-11 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010546901A Active JP5844045B2 (ja) | 2008-02-12 | 2009-02-12 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2014244283A Pending JP2015091239A (ja) | 2008-02-12 | 2014-12-02 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018245609A Active JP6837469B2 (ja) | 2008-02-12 | 2018-12-27 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2021019383A Active JP7277493B2 (ja) | 2008-02-12 | 2021-02-09 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2023076515A Withdrawn JP2023109807A (ja) | 2008-02-12 | 2023-05-08 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
| JP2025097940A Pending JP2025148351A (ja) | 2008-02-12 | 2025-06-11 | 疾病の薬理シャペロン治療に対する応答性を予測する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US8592362B2 (https=) |
| EP (4) | EP2946785B1 (https=) |
| JP (7) | JP5844045B2 (https=) |
| AU (7) | AU2009214648B2 (https=) |
| CA (1) | CA2715407C (https=) |
| CY (3) | CY1116466T1 (https=) |
| DK (3) | DK3470077T3 (https=) |
| ES (3) | ES2541933T3 (https=) |
| HR (3) | HRP20150728T1 (https=) |
| HU (3) | HUE042882T2 (https=) |
| LT (2) | LT2946785T (https=) |
| MX (1) | MX2010008835A (https=) |
| PL (3) | PL2252313T3 (https=) |
| PT (3) | PT2252313E (https=) |
| SI (3) | SI2252313T1 (https=) |
| WO (1) | WO2009102895A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| JP2011517556A (ja) * | 2008-03-12 | 2011-06-16 | アミカス セラピューティックス インコーポレイテッド | ポンペ病のための治療選択肢を診断し評価するための検定 |
| TW201117810A (en) * | 2009-10-01 | 2011-06-01 | Baylor Res Inst | Treatment of male-pattern baldness by local induction of the metabolic defect of fabry disease |
| US20120283290A1 (en) * | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| CN114540327B (zh) | 2014-09-30 | 2026-03-24 | 阿米库斯治疗学公司 | 具有增强的碳水化合物的高强度酸性α-葡糖苷酶 |
| WO2016149508A1 (en) * | 2015-03-19 | 2016-09-22 | Shire Human Genetic Therapies, Inc. | Mrna therapy for pompe disease |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| KR20250007693A (ko) | 2015-12-30 | 2025-01-14 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| HRP20231465T1 (hr) | 2015-12-30 | 2024-03-01 | Amicus Therapeutics, Inc. | Poboljšana kisela alfa-glukozidaza za liječenje pompeove bolesti |
| KR20190087673A (ko) * | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| SMT202200279T1 (it) | 2016-03-30 | 2022-09-14 | Amicus Therapeutics Inc | Formulazioni comprendenti alfa-glucosidasi acida ricombinante |
| CA3019354A1 (en) * | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| AU2017239641A1 (en) | 2016-03-30 | 2018-10-18 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| TW202408513A (zh) | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
| JP6546135B2 (ja) | 2016-08-24 | 2019-07-17 | 株式会社ノリタケカンパニーリミテド | 積層造形焼成体、積層造形焼成体の製造方法および積層造形焼成体製造用キット |
| KR102712926B1 (ko) * | 2016-10-20 | 2024-10-07 | 상가모 테라퓨틱스, 인코포레이티드 | 파브리병의 치료를 위한 방법 및 조성물 |
| EA039750B1 (ru) * | 2017-03-30 | 2022-03-10 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| SMT202300187T1 (it) | 2017-05-15 | 2023-07-20 | Amicus Therapeutics Inc | Alfa-glucosidasi acida umana ricombinante |
| RS65230B1 (sr) | 2017-05-30 | 2024-03-29 | Amicus Therapeutics Inc | Migalastat za lečenje pacijenata koji boluju od fabrijeve bolesti sa oštećenjem bubrega |
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| SG11202000423XA (en) | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| US20200222377A1 (en) | 2017-08-28 | 2020-07-16 | Amicus Therapeutics, Inc. | Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease |
| PT3749308T (pt) | 2018-02-06 | 2024-01-25 | Amicus Therapeutics Inc | Tratamento de pacientes com doença de fabry clássica com migalastato |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| US12594268B2 (en) | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| NL2021840B1 (en) | 2018-10-19 | 2020-05-13 | Univ Leiden | Pharmacological Chaperones For Enzyme Treatment Therapy |
| WO2020046132A1 (en) | 2018-08-31 | 2020-03-05 | Leiden University | Pharmacological chaperones for enzyme treatment therapy |
| TW202042812A (zh) | 2019-01-22 | 2020-12-01 | 美商阿米庫斯醫療股份有限公司 | 減少法布瑞氏症患者中之腦血管事件之方法 |
| MX2021015352A (es) | 2019-06-11 | 2022-04-06 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
| KR20220044560A (ko) * | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| EP4025242A1 (en) | 2019-09-06 | 2022-07-13 | Amicus Therapeutics, Inc. | Method for capturing and purification of biologics |
| KR20220150902A (ko) | 2020-02-10 | 2022-11-11 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 파브리 질병을 치료하는 방법 |
| AU2021230371A1 (en) * | 2020-03-06 | 2022-09-29 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| CA3225511A1 (en) | 2021-07-12 | 2023-01-19 | Franklin Johnson | Methods of treating fabry disease in pediatric patients |
| EP4518885A1 (en) | 2022-05-05 | 2025-03-12 | Amicus Therapeutics, Inc. | Methods for treating pompe disease |
| WO2024119091A1 (en) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Fexamethods for treating infantile-onset pompe disease in pediatric patients |
| AR131256A1 (es) | 2022-12-02 | 2025-03-05 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de pompe de inicio tardío en pacientes pediátricos |
| US20240197706A1 (en) | 2022-12-13 | 2024-06-20 | Amicus Therapeutics, Inc. | Methods of improving the pharmacokinetics of migalastat |
| WO2026006625A1 (en) | 2024-06-26 | 2026-01-02 | Amicus Therapeutics, Inc. | Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US264467A (en) * | 1882-09-19 | Chables h | ||
| US203019A (en) * | 1878-04-30 | Improvement in circuits for acoustic or telephonic telegraphs | ||
| US270486A (en) * | 1883-01-09 | Bundle-separating attachment for self-binding harvesters | ||
| US21381A (en) * | 1858-08-31 | Bracelet | ||
| US3586908A (en) | 1969-02-28 | 1971-06-22 | Robert E Vosteen | Automatic potential control system for electrophotography apparatus |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US6270954B1 (en) | 1996-04-10 | 2001-08-07 | The Regents Of The University Of California | Correction of genetic defects using chemical chaperones |
| US5900360A (en) | 1996-04-10 | 1999-05-04 | Welch; William J. | Correction of genetic defects using chemical chaperones |
| US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US6244113B1 (en) | 1999-10-29 | 2001-06-12 | University Of Alabama In Huntsville | Method and apparatus for measuring microgravity acceleration |
| US7842470B2 (en) * | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| SI2027137T1 (sl) | 2005-06-08 | 2015-06-30 | Amicus Therapeutics, Inc. | Čiščenje imino in amino sladkorja |
| AU2006254796B2 (en) * | 2005-06-08 | 2012-08-16 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| WO2007089591A2 (en) * | 2006-01-27 | 2007-08-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for high throughput screening of pharmacological chaperones |
| PL2533050T6 (pl) * | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| PL1860101T3 (pl) | 2006-05-24 | 2011-10-31 | Amicus Therapeutics Inc | Sól winianu izofagominy i sposoby zastosowania |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| MX2009011473A (es) | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| WO2010048532A1 (en) | 2008-10-24 | 2010-04-29 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| US9206457B2 (en) | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| AU2010254092B2 (en) | 2009-05-26 | 2015-11-12 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| WO2011063048A2 (en) | 2009-11-17 | 2011-05-26 | Baylor Research Institute | Urinary triaosylceramide (gb3) as a marker of cardiac disease |
| SG10201604757RA (en) | 2011-03-11 | 2016-08-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
| WO2014014938A1 (en) | 2012-07-17 | 2014-01-23 | Amicus Therapeutics, Inc. | Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| KR20190087673A (ko) | 2016-03-22 | 2019-07-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| TW202408513A (zh) | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
| US11357834B2 (en) | 2017-01-10 | 2022-06-14 | Amicus Therapeutics, Inc. | Recombinant α-galactosidase A for treatment of Fabry disease |
| CA3224546C (en) | 2017-05-30 | 2026-02-24 | Amicus Therapeutics, Inc. | Use of migalastat in the treatment of fabry patients |
| SG11202000423XA (en) | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| US20200222377A1 (en) | 2017-08-28 | 2020-07-16 | Amicus Therapeutics, Inc. | Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease |
| KR20200128676A (ko) | 2018-02-06 | 2020-11-16 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도 |
| PT3749308T (pt) | 2018-02-06 | 2024-01-25 | Amicus Therapeutics Inc | Tratamento de pacientes com doença de fabry clássica com migalastato |
| US12594268B2 (en) | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| MX2021015352A (es) | 2019-06-11 | 2022-04-06 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
-
2009
- 2009-02-12 EP EP15162630.6A patent/EP2946785B1/en active Active
- 2009-02-12 ES ES09710178.6T patent/ES2541933T3/es active Active
- 2009-02-12 PL PL09710178T patent/PL2252313T3/pl unknown
- 2009-02-12 EP EP18201960.4A patent/EP3470077B1/en active Active
- 2009-02-12 SI SI200931229T patent/SI2252313T1/sl unknown
- 2009-02-12 PT PT97101786T patent/PT2252313E/pt unknown
- 2009-02-12 JP JP2010546901A patent/JP5844045B2/ja active Active
- 2009-02-12 MX MX2010008835A patent/MX2010008835A/es active IP Right Grant
- 2009-02-12 HU HUE15162630A patent/HUE042882T2/hu unknown
- 2009-02-12 HU HUE18201960A patent/HUE051377T2/hu unknown
- 2009-02-12 ES ES18201960T patent/ES2836121T3/es active Active
- 2009-02-12 EP EP09710178.6A patent/EP2252313B1/en active Active
- 2009-02-12 PT PT15162630T patent/PT2946785T/pt unknown
- 2009-02-12 DK DK18201960.4T patent/DK3470077T3/da active
- 2009-02-12 SI SI200931920T patent/SI2946785T1/sl unknown
- 2009-02-12 HU HUE09710178A patent/HUE026543T2/hu unknown
- 2009-02-12 DK DK09710178.6T patent/DK2252313T3/en active
- 2009-02-12 AU AU2009214648A patent/AU2009214648B2/en active Active
- 2009-02-12 PL PL15162630T patent/PL2946785T3/pl unknown
- 2009-02-12 WO PCT/US2009/033963 patent/WO2009102895A2/en not_active Ceased
- 2009-02-12 SI SI200932099T patent/SI3470077T1/sl unknown
- 2009-02-12 PT PT182019604T patent/PT3470077T/pt unknown
- 2009-02-12 CA CA2715407A patent/CA2715407C/en active Active
- 2009-02-12 LT LTEP15162630.6T patent/LT2946785T/lt unknown
- 2009-02-12 EP EP20192637.5A patent/EP3824900A1/en active Pending
- 2009-02-12 HR HRP20150728TT patent/HRP20150728T1/hr unknown
- 2009-02-12 LT LTEP18201960.4T patent/LT3470077T/lt unknown
- 2009-02-12 DK DK15162630.6T patent/DK2946785T3/en active
- 2009-02-12 ES ES15162630T patent/ES2716502T3/es active Active
- 2009-02-12 PL PL18201960T patent/PL3470077T3/pl unknown
-
2010
- 2010-08-12 US US12/855,468 patent/US8592362B2/en not_active Ceased
- 2010-08-20 US US12/860,611 patent/US20110152319A1/en not_active Abandoned
-
2013
- 2013-10-15 US US14/054,369 patent/US9095584B2/en active Active
-
2014
- 2014-09-10 AU AU2014221321A patent/AU2014221321B2/en active Active
- 2014-12-02 JP JP2014244283A patent/JP2015091239A/ja active Pending
-
2015
- 2015-06-05 US US14/731,603 patent/US9545397B2/en active Active
- 2015-07-08 CY CY20151100595T patent/CY1116466T1/el unknown
-
2016
- 2016-03-01 JP JP2016039171A patent/JP6672013B2/ja active Active
- 2016-07-20 AU AU2016206297A patent/AU2016206297A1/en not_active Abandoned
- 2016-09-19 US US15/268,662 patent/US20170003301A1/en not_active Abandoned
-
2017
- 2017-11-30 AU AU2017268649A patent/AU2017268649A1/en not_active Abandoned
-
2018
- 2018-07-26 US US16/046,247 patent/US10813921B2/en active Active
- 2018-12-17 US US16/222,305 patent/USRE48608E1/en active Active
- 2018-12-27 JP JP2018245609A patent/JP6837469B2/ja active Active
-
2019
- 2019-01-22 HR HRP20190143TT patent/HRP20190143T1/hr unknown
- 2019-01-24 CY CY20191100100T patent/CY1121386T1/el unknown
- 2019-08-20 AU AU2019219727A patent/AU2019219727B2/en active Active
-
2020
- 2020-10-26 US US17/079,859 patent/US20250082621A9/en active Pending
- 2020-11-17 HR HRP20201827TT patent/HRP20201827T1/hr unknown
- 2020-11-25 CY CY20201101114T patent/CY1123816T1/el unknown
-
2021
- 2021-02-09 JP JP2021019383A patent/JP7277493B2/ja active Active
- 2021-08-20 AU AU2021218172A patent/AU2021218172A1/en not_active Abandoned
-
2023
- 2023-05-08 JP JP2023076515A patent/JP2023109807A/ja not_active Withdrawn
-
2024
- 2024-09-24 AU AU2024219997A patent/AU2024219997A1/en active Pending
-
2025
- 2025-06-11 JP JP2025097940A patent/JP2025148351A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016163571A5 (https=) | ||
| JP2017506624A5 (https=) | ||
| JP2016147915A5 (https=) | ||
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| JP2009280621A5 (https=) | ||
| JP2016106150A5 (https=) | ||
| JP2015532296A5 (https=) | ||
| JP2018184462A5 (https=) | ||
| JP2017528507A5 (https=) | ||
| FI3457135T3 (fi) | Fabryn taudin hoitovaihtoehtoja | |
| RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| JP2017075173A5 (https=) | ||
| FI3840753T3 (fi) | Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| BR112017013253A2 (pt) | comprimidos de desintegração oral, processo para produzir comprimido de desintegração oral contendo tofacitinibe ou seus sais farmaceuticamente aceitáveis, processo para produzir comprimido de desintegração oral, desintegrante, e edulcorantes | |
| JP2020529995A5 (https=) | ||
| JP2020536085A5 (https=) | ||
| PE20191240A1 (es) | Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| JP2019504848A5 (https=) | ||
| IL299338A (en) | Heterocyclic derivatives, pharmaceutical preparations and their use for the treatment, amelioration or prevention of fibrotic disease | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| FI2608789T4 (fi) | 1-[2-(2,4-dimetyyli-fenyylisulfanyyli)fenyyli]piperatsiinin terapeuttisia käyttötapoja |